Our aim was to clarify the risk factors for graft loss within the first 90 days of kidney transplantation.
Introduction
Kidney transplantation is the most effective treatment available for patients with end-stage renal disease (ESRD). However, in 2014, only 17,107 kidney transplants were performed in the United States leaving over 80,000 people waiting for a transplant [1] . Because of the need for more donors, there has been increasing utilization of suboptimal kidneys, which are associated with inferior outcomes [2, 3] . Additionally, it has been suggested that the use of these allografts is linked to early graft loss (EGL) [4] .
EGL is defined as graft loss occurring within 90 days of kidney transplantation. It is relatively rare, occurring after approximately 5% of transplantations [5] . Causes of EGL include: patient death, renal artery or vein thrombosis, acute rejection (AR), and primary non-function (PNF). Very short-term outcomes after kidney transplantation are understudied. Additionally, there have been few reports on risk factors for EGL, and those that have been published are limited to single center analyses [4, 5] .
Thus, our aim was to clarify those risk factors. Additionally, we sought to determine if there was a difference in the risk factors associated with each specific cause of EGL. We utilized the United Network for Organ Sharing (UNOS) database and our own single center database for our analysis. We hypothesized that the rate of EGL nationwide would be similar to that reported in prior single center analyses.
Materials and methods

UNOS database
Data containing kidney transplant donor and recipient (n = 56,883) information from June 6, 2011 through June 30, 2015 was extracted from the UNOS database. Recipients of living donor organs and simultaneous liver, pancreas, intestine, lung or heart transplants were excluded. Details regarding the recipient and donor demographics were queried. Recipient characteristics obtained included age, gender, BMI, time on waitlist, dialysis status, clinical status (ICU vs hospitalized vs home) and mechanical ventilatory needs at time of transplantation. Donor characteristics obtained included age, gender, race, BMI, creatinine, bilirubin, donor risk index (DRI), expanded criteria donor (ECD), and donation after cardiac death (DCD). Additional perioperative details were queried, including human leukocyte antigen (HLA) mismatch level, warm ischemia time, and cold ischemia time.
Single center database
We analyzed our database of 676 patients who received kidney transplants and were induced with Alemtuzumab (ALE) at the University of Toledo Medical Center in Toledo, Ohio between March 2004 and November 2015. Patient data was reviewed using TransChart electronic medical record software (TransChart LLC, Dublin, Ohio). Donor information included: sex, age, ethnicity, presence of hypertension, presence of diabetes mellitus, type of donor and terminal creatinine. Recipient information included: sex, age, ethnicity, blood type, type of graft received, panel reactive antibody (PRA), and number of transplants (Table 1) . EGL was defined as the occurrence of renal artery or vein thrombosis, ACR, AMR, or PNF within the first 90 days post-transplantation.
Prior to transplantation, patient profiles were cross-matched for T and B cell status via flow cytometry. All patients included in our study were negative cross-matches for both T and B cells. All cases of acute rejection were biopsy-proven.
Patients were pretreated with 25 mg of diphenhydramine intravenously (IV). At the time of the procedure, induction immunosuppression with methylprednisolone 500 mg (IV) (Solu-Medrol, Pfizer, New York, NY), mycophenolate sodium 540 mg by mouth (PO) (Myfortic, Novartis Pharmaceuticals, Basel, Switzerland) and ALE 30 mg IV was administered.
The post-operative steroid taper consisted of: methylprednisolone 250 mg IV on post-operative day 1, methylprednisolone 125 mg IV on post-operative day 2, prednisone 60 mg PO on post-operative day 3, prednisone 40 mg PO on post-operative day 4, and, finally, prednisone 20 mg PO on post-operative day 5. Patients at high-risk for rejection were continued indefinitely on prednisone 5-10 mg PO.
Starting on post-operative day 1, Tacrolimus 1.5 mg PO (Prograf, Astellas Pharma, Tokyo, Japan) and mycophenolate sodium 540 mg PO twice per day were given. Tacrolimus levels were measured and titrated to the correct dose. Side effects permitting, mycophenolate sodium was increased to 720 mg PO at discharge.
Antimicrobial prophylaxis was started post-operatively with sulfamethoxazole (800 mg)-trimethoprim (160 mg) 1 tab PO (Bactrim DS, AR Scientific, Philadelphia, PA) 3 times per week and clotrimazole troche 10 mg dissolved in the mouth 4 times per day following oral care. In the event of a cytomegalovirus (CMV) mismatch, daily valgancyclovir 450 mg PO (Valcyte, Hoffman-La Roche, Basel, Switzerland) was prescribed. The diagnosis of CMV mismatch was made by determining the IgM antibodies to CMV by polymerase chain reaction (PCR).
Continuous variables were presented in medians and were compared using t-tests or the Mann-Whitney U test when appropriate. Categorical variables including gender, ethnicity, education level, delayed graft function, and early rejection were presented in terms of percentage of the total number within the group. They were compared with Pearson's Chi-square or Fisher's Exact Test. Multivariate survival analysis was done using Cox regression analysis with multivariate factors selected from univariate results and with patient ethnicity included for comparison. Type I error level was set at 0.05. All statistical analyses for single center were conducted using IBM SPSS ver23 (IBM Corp., Armonk, NY) and analyses for UNOS data were conducted using Stata ver14 (StataCorp LLC, College Station, TX).
Results
UNOS database
The rate of EGL in the UNOS database was 1,903 (3.35%) out of 56,883 patients. Increased age, elevated BMI, and recipient diabetes were significantly associated with higher rates of EGL due to patient death when compared to the non-EGL group (p<0.001, p=0.0220, and p<0.001, respectively) ( Table 2 ). Recipients on the waitlist for longer periods of time had a significantly higher incidence of EGL due to patient death compared to the non-EGL group (p=0.0019) ( Table 2) . Patients who were in the ICU or hospital at the time of transplant experienced EGL due to patient death at a significantly higher rate compared to the non-EGL group (p=0.012) ( Table 2) . Upon multivariate analysis, only recipient age was a significant predictor of EGL due to patient death (HR: 1.04, CI: 1.03-1.04, p<0.001). Incidence of EGL due to thrombosis was significantly more common in males and in recipients without diabetes (p=0.004 and p=0.017, respectively) ( Table 3 ). Patients who were at home directly prior to transplantation experienced EGL due to thrombosis at a significantly higher rate compared to the non-EGL group (p=0.045) ( Table 3 ). Multivariate analysis revealed no significant predictors of EGL due to thrombosis. EGL due to PNF was significantly more common in female recipients and recipients without diabetes (p=0.004 and p=0.01, respectively) ( Table 4 ). Recipient age was found to be marginally protective for recipients with EGL due to PNF (HR: 0.99, CI: 0.98-0.99, p=0.039). EGL due to AR was significantly more common in recipients with elevated BMI (p=0.0003) ( Table 5 ). EGL due to AR was also significantly more common in recipients who had longer times spent on the waitlist (1193.52 ± 964.64 days vs. 936 ± 774.01 days; p=0.0004) ( 
Recipient Factors
Single center
A total of 676 patients underwent kidney transplantation at our institution during the study period. 30 (4.4%) patients had EGL ( Table 7) . Recipients of expanded criteria donor (ECD) grafts had a significantly higher rate of EGL compared to controls (44% and 10.3%, respectively; p<0.001, Table 1 ). Patients who experienced EGL received grafts from significantly older donors compared to controls (46.5 years and 38.3 years, respectively; p=0.003, Table 1 ). Donor body mass index (BMI) was significantly higher in recipients with EGL compared to controls (30 kg/m 2 and 26.9 kg/m 2 , respectively; p=0.004, Table 1 ). Recipients with EGL received grafts from donors with significantly higher Kidney Donor Profile Indices (KDPI) compared to controls (60.4 and 38.9, respectively; p=0.001, Table 1 ). All other recipient and donor demographics are listed in Table 1 .
Graft loss due to graft thrombosis was significantly higher in recipients with EGL compared to controls (24.1% and 0.7%, respectively; p<0.05). Graft loss because of AR was not significantly different in the EGL group compared to controls (13.8% and 15.2%, respectively; p>0.05). The rate of death as a cause of graft loss did not differ significantly between recipients with EGL and controls (36.7% and 46.9%, respectively; p>0.05; Table 7 ). 1-, 3-, and 5-year patient survival was significantly lower in recipients with EGL compared to controls (63%, 50%, 50% and 97.5%, 91.4%, 86%, respectively; all p<0.001) ( Table 8 ). There was no significant difference in the rate of rejection between recipients with EGL and controls (33.3% and 26.6%, respectively; p=0.406). The median number of days until rejection in the EGL group was significantly less than controls (18.8 days and 308.4 days, respectively; p=0.001). The median number of days until the death for those with EGL was significantly less than controls (327.9 days and 1145.8 days, respectively; p<0.001). Multivariate analysis suggested that ECD (HR=5.163, CI=2.217-12.027, p<0.001) and donor BMI (HR=1.148, CI=1.069-1.232, p<0.001) were significant predictors of EGL.
Discussion
EGL after kidney transplantation is a relatively rare, yet catastrophic event, occurring at rates of 4.4% at our center and 3.35% among UNOS patient data. Thus, it is important to understand the risk factors associated with EGL in order to better inform clinical decision-making. We defined EGL as renal artery or vein thrombosis, ACR, AMR, PNF, or recipient death occurring within 90 days of kidney transplantation. Other reports defined EGL as occurring within 30 days of kidney transplantation [4, 5] . We chose a 90-day window because any patients who lost their allograft during this time period would be able to retain their pre-transplantation listing time.
The limited, single-center analyses that exist on EGL to date have suggested that increased donor age, DCD donor type, ECD donor type, and increased CIT were associated with EGL [4, 5] . Cox regression analysis of our single-center data confirmed that ECD donor type was
Donor Characteristics
EGL-Pt. Death EGL-Thrombosis EGL-PNF EGL-Acute Rejection Non-EGL a significant predictor of EGL. The results of the review of UNOS data, however, were not as straightforward. Our data suggest that increased donor age is significantly associated with only EGL due to patient death, PNF, and AR. DCD donor type is associated with EGL due to patient death, thrombosis, and PNF, but not AR. Finally, ECD donor type is significantly associated with EGL due to patient death and AR. Multivariate analysis revealed, however, that none of these factors was a significant predictor of EGL vs. non-EGL. In this regard, the results of our UNOS review differ from those of both our own single-center review and those of Hamed et al. and Phelan et al. [4, 5] .
Given that data on EGL is limited, we sought to compare the potential risk factors presented in our data to those reported for thrombosis, AR, PNF, and patient death outside the scope of EGL to determine how our findings, in the context of EGL, compare.
Many have reported increased donor age as a risk factor for renal allograft thrombosis [6] [7] [8] . In the context of EGL, our data indicate that there was no significant difference in donor age between recipients who did not experienced EGL and those who experienced EGL due to thrombosis. A major risk factor for graft thrombosis is a history of thrombosis [4, 7] . Unfortunately, our data did not include whether or not recipients had a history of thrombosis thus preventing us from drawing additional conclusions.
Lebranchu et al. reported that older donor age was a significant predictor of AR following transplantation. Our results correlate with their findings and further, suggest that in the context of EGL, increased donor age is also associated with an increased risk for recipient death and PNF. They also suggested that African American ethnicity and extended CIT were related to increased rates of AR. Our data, however, suggest that there was no significant difference in the number of African American recipients who experienced AR as a cause of EGL and those who did not. Additionally, there was no significant difference in CIT between the two groups. Delayed graft function is a well-known risk factor for AR [9, 10] . Unfortunately, we did not have data on the recipients who experienced delayed graft function.
Hamed et al. [4] found an increased incidence of PNF in DCD kidneys, which they believed was due to warm ischemic injury as these kidneys are more vulnerable to ischemic reperfusion injury. Similarly, Snoejis, et al. noted that patients who suffered from PNF typically had impaired hemodynamic status during the time of transplant [11] . During the surgery, these patients have a lower BP than those with delayed or immediate graft function. Our data supports these findings as an increase in WIT and CIT can increase the risk of EGL. Our results along with these studies demonstrate that PNF may reflect the quality of the donor organ more than the recipient.
Regarding patient mortality, Debout et al. demonstrated a significant proportional increase in recipient mortality for each additional hour of CIT. We report significantly longer CIT in recipients who experienced EGL due to patient death. CIT was also significantly greater in recipients who experienced EGL due to thrombosis and acute rejection. It has also been reported that recipients of ECD grafts have a higher risk of death in the early post-transplant period [12] . Our data are similar, recipients who suffered EGL due to death were significantly more likely to have received an ECD graft.
In recipients who experience EGL, it is important to know what happened to them after graft loss. In analyzing the post-EGL outcomes of patients at our own institution, we found 20 recipients who experienced EGL attributable to causes other than patient death. Of these, 3 were re-transplanted and 3 died while waiting for a re-transplant. The remaining 14 are still awaiting re-transplant to our knowledge.
Our analysis has a number of strengths. Primarily, it includes data from both a single center (similar to previous analyses on EGL) and the UNOS database. Furthermore, we were able to identify risk factors specific to certain causes of EGL using the UNOS data. Finally, we utilized a relatively large sample size. One weakness was the lack of certain data points, such as previous history of thrombosis. Additionally, the relative lack of other reports on the topic of EGL make it difficult to compare out conclusions to others [13] [14] [15] [16] [17] .
Conclusion
The rates of EGL were 4.4% at our center and 3.35% among UNOS patient data. Although an obvious trend is difficult to discern, our data generally suggest that sub-optimal allografts are associated with an increase in EGL due to a variety of factors. Given these results, we believe transplant providers should use caution and increased monitoring of recipients receiving what could be considered suboptimal allografts.
